Loading...

Jo Chien, MD

TitleAssociate Professor
InstitutionUniversity of California San Francisco
DepartmentMedicine
Address1600 Divisadero
San Francisco CA 94115
Phone415-353-7070
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Harvard UniversityM.D.2003School of Medicine

    Collapse Overview 
    Collapse Overview
    Dr. A. Jo Chien specializes in breast cancer, with special expertise in tumors that are called HER2+ (human epidermal growth factor receptor 2), typically a more aggressive type of cancer. Her primary research interests include HER2+, breast cancer in young women, and fertility problems related to cancer treatment.

    Chien graduated from Harvard Medical School in 2003 and completed a residency in internal medicine at Massachusetts General Hospital in Boston. She was a fellow in the hematology and oncology at UCSF from 2006 to 2009. Chien received the Massachusetts Medical Society and Alliance Charitable Foundation International Health Grant in 2003, American Society of Clinical Oncology (ASCO) Young Investigator Award in 2008; ASCO Foundation Merit Award in 2008; and American Cancer Society Postdoctoral Fellowship in 2008. She has published numerous articles in medical journals related to her breast cancer research. Chien is a member of the American Society of Clinical Oncology and the American Association of Cancer Research. She is an assistant professor of medicine at UCSF.


    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Global Health
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Letourneau JM, Sinha N, Wald K, Harris E, Quinn M, Imbar T, Mok-Lin E, Chien J, Rosen M. Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer. Hum Reprod. 2017 Oct 01; 32(10):2123-2129. PMID: 28938748.
      View in: PubMed
    2. Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien J, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6400-6410. PMID: 28790114.
      View in: PubMed
    3. Chien J, Rugo HS. Tyrosine Kinase Inhibitors for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Is Personalizing Therapy Within Reach? J Clin Oncol. 2017 Sep 20; 35(27):3089-3091. PMID: 28783451.
      View in: PubMed
    4. Chien J, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP. Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017 08; 165(1):161. PMID: 28660429.
      View in: PubMed
    5. Chien J, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017 Aug; 165(1):151-159. PMID: 28503722.
      View in: PubMed
    6. Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien J, Park JW, Rugo HS. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2017 Mar 01; 3(3):313-319. PMID: 27832260.
      View in: PubMed
    7. Jones EF, Ray KM, Li W, Seo Y, Franc BL, Chien J, Esserman LJ, Pampaloni MH, Joe BN, Hylton NM. Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer. Clin Breast Cancer. 2017 06; 17(3):e155-e159. PMID: 28110902.
      View in: PubMed
    8. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien J, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):11-22. PMID: 27406346.
      View in: PubMed
    9. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien J, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34. PMID: 27406347.
      View in: PubMed
    10. Chien J, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30. PMID: 26875185.
      View in: PubMed
    11. Rugo HS, Chien J. HER2-positive breast cancer: is more treatment better? Lancet Oncol. 2016 Mar; 17(3):268-70. PMID: 26874902.
      View in: PubMed
    12. Chien J, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman LJ, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP. Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Res Treat. 2015 Aug; 153(1):173-81. PMID: 26208485.
      View in: PubMed
    13. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien J, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 01; 21(13):2911-5. PMID: 25712686; PMCID: PMC4490043.
      View in: PubMed, PubMed Central
    14. Chien J, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol. 2014 May 10; 32(14):1472-9. PMID: 24711549; PMCID: PMC4017711.
      View in: PubMed, PubMed Central
    15. Boutrus RR, Abi Raad RF, Kuter I, Ancukiewicz M, Roberts L, Solomon N, Ngo T, Borick H, Ryan P, Moy B, Gadd M, Chien J, Younger J, Smith B, Taghian AG, Harris L. Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy. Int J Biol Markers. 2013 Apr 23; 28(1):17-23. PMID: 23015398.
      View in: PubMed
    16. DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien J, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 01; 19(11):2817-23. PMID: 23470967; PMCID: PMC4096560.
      View in: PubMed, PubMed Central
    17. Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien J, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol. 2012 Dec 20; 30(36):4584-6; author reply 4588-9. PMID: 23169510.
      View in: PubMed
    18. Chien J, Rugo HS. Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(1):1-12. PMID: 23143215; PMCID: PMC3528960.
      View in: PubMed, PubMed Central
    19. Bock M, Moore D, Hwang J, Shumay D, Lawson L, Hamolsky D, Esserman L, Rugo H, Chien J, Park J, Munster P, Melisko M. The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors. Breast Cancer Res Treat. 2012 Aug; 134(3):1327-35. PMID: 22798157.
      View in: PubMed
    20. Rugo HS, Chien J, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, Nulsen B, Dickler MN. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2012 Jul; 134(1):13-20. PMID: 22198412; PMCID: PMC3397213.
      View in: PubMed, PubMed Central
    21. Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien J, Melisko ME, Cedars MI, Rosen MP. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012 Mar 15; 118(6):1710-7. PMID: 21887678; PMCID: PMC3235264.
      View in: PubMed, PubMed Central
    22. Letourneau JM, Ebbel EE, Katz PP, Oktay KH, McCulloch CE, Ai WZ, Chien J, Melisko ME, Cedars MI, Rosen MP. Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer. Cancer. 2012 Apr 01; 118(7):1933-9. PMID: 21850728; PMCID: PMC3220922.
      View in: PubMed, PubMed Central
    23. Chien J, Rugo HS. The cardiac safety of trastuzumab in the treatment of breast cancer. Expert Opin Drug Saf. 2010 Mar; 9(2):335-46. PMID: 20175700.
      View in: PubMed
    24. Chien J, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 01; 15(17):5569-75. PMID: 19706807; PMCID: PMC3029022.
      View in: PubMed, PubMed Central
    25. Jo Chien A, Rugo HS. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer. Cancer Treat Res. 2009; 151:197-215. PMID: 19593514.
      View in: PubMed
    26. Chien J, Moasser MM. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol. 2008 Apr; 35(2 Suppl 2):S1-S14; quiz S39. PMID: 18410794.
      View in: PubMed
    27. Chien J, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol. 2006 Nov 20; 24(33):5305-12. PMID: 17114665.
      View in: PubMed
    Jo's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (144) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (51) people
    _
    Related Authors
    People who share related concepts with this person.
    See all (54) people
    _
    ↑